Clinical trials
Capecitabine clinical trials
Below are recruiting capecitabine clinical trials, each written for real people, not researchers. We’re tracking 288 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07060807RecruitingPhase 3
Study of Patritumab Deruxtecan for Advanced HR+/HER2- Breast Cancer
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
Daphne, AlabamaAges 18 years+ - NCT06393374RecruitingPhase 3
Study of a new drug combination for residual TNBC after initial treatment
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT04615013RecruitingPhase 1
NBTXR3 with chemoradiation for esophageal cancer treatment
This early-phase study tests adding NBTXR3 (a special treatment given into the tumor) to standard chemotherapy and radiation for esophageal cancer. The goal is to see if it can improve cancer control and to learn about safety and dosing.
Houston, TexasAges 18 years+ - NCT07750951RecruitingPhase 2
Combination therapy before surgery for advanced rectal cancer
This trial tests a combination of two immunotherapy drugs and chemotherapy given before surgery for a type of rectal cancer that has a specific genetic marker (MSI-H/dMMR). The goal is to shrink the tumor and improve the chances of successful surgery.
Xi'an, ShaanxiAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Cerritos, CaliforniaAges 18 years+ - NCT06957886RecruitingPhase 3
Study of BL-M07D1 vs chemo for HER2-low breast cancer
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT06928584RecruitingPhase 2
Shorter Radiation Plus Immunotherapy for Recurrent Rectal Cancer
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06761417RecruitingPhase 2
Liposomal mitoxantrone for children and young adults with relapsed solid tumors
This trial tests a new form of chemotherapy (liposomal mitoxantrone) for children, adolescents, and young adults whose solid tumors have come back or not responded to treatment. The goal is to see if this combination regimen can help shrink tumors.
BeijingAges 6–24 - NCT06462053RecruitingPhase 2
Short radiotherapy plus chemo and immunotherapy for early low rectal cancer
This study is testing whether a short course of radiation combined with chemotherapy and an immunotherapy drug works better than the standard longer radiation and chemotherapy for early-stage rectal cancer that is low in the rectum. The goal is to see if this shorter treatment can help patients avoid surgery or have a better outcome.
ShanghaiAges 18–75 - NCT06217185RecruitingPhase 4
Pyrotinib and trastuzumab with chemo for HER2+ advanced breast cancer
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
Shijiazhuang, HebeiAges 18–70 - NCT06281405RecruitingPhase 2
CAPOX and immunotherapy with or without radiation for rectal cancer
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
ShanghaiAges 18–70 - NCT05972655RecruitingPhase 2
Testing shorter rectal radiation with chemotherapy plus immunotherapy
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
Hanzhou, ZhejiangAges 18–75 - NCT05851924RecruitingPhase 2
Nalirifox plus radiation for nonmetastatic pancreatic cancer
This trial studies Nalirifox (chemotherapy) given together with radiation therapy for pancreatic ductal adenocarcinoma that has not spread to distant organs. It may help shrink the cancer and improve local control, especially when surgery is not an option right now.
Basking Ridge, New JerseyAges 18 years+ - NCT05367635RecruitingPhase 1
Testing a new drug for advanced stomach cancers with CLDN18.2
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT05585814RecruitingPhase 2
New chemo plus immunotherapy before rectal surgery
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
ShanghaiAges 18–75 - NCT05555888RecruitingPhase 2
Immunotherapy plus short-course radiation for early rectal cancer
This study tests whether combining immunotherapy with a short course of radiation given before surgery can improve outcomes in early-stage rectal cancer. It may help the immune system work better against the tumor before it is removed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05300269RecruitingPhase 2
Test drug SHR-1701 with chemo and radiation for rectal cancer
This trial studies whether adding SHR-1701 to standard chemotherapy and long-course radiation can improve treatment for locally advanced rectal cancer that can be removed by surgery. It’s mainly for people who have not had prior rectal cancer treatment and who fit several health and cancer-spread requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05412082RecruitingPhase 1
Smart chemo and radiation plan for locally advanced rectal cancer
This Phase 1 study tests a “smart” total treatment plan using chemotherapy (chemo) and radiation before surgery for people with locally advanced rectal cancer. The goal is to see if this approach is safe and can work well while helping plan treatment based on your situation.
Miami, FloridaAges 18 years+ - NCT05062317RecruitingPhase 2
Blood test-guided chemotherapy after liver tumor removal
This trial uses a blood test (ctDNA, a sign of cancer cells shedding into the blood) to help guide chemotherapy after surgery to remove colorectal liver metastases. It may help patients get the right chemotherapy plan after their operation, potentially based on whether cancer material is still detectable.
Houston, TexasAges 18 years+ - NCT04495296RecruitingPhase 1/Phase 2
TST001 for advanced or metastatic solid tumors
This Phase 1/2 study tests TST001, and sometimes a combination with other cancer medicines, to see how safe it is and how well it may work in advanced or metastatic solid tumors. You might be eligible if you have certain tumor types and lab/health requirements, and if your tumor tissue shows specific marker results (depending on the study part).
Bengbu, AnhuiAges 18 years+ - NCT03801876RecruitingPhase 3
Proton versus photon radiation for esophageal cancer
This trial compares proton therapy and standard photon (X-ray) radiation for treating esophageal cancer. It looks to see which approach works better and is safer for people who need chemoradiation.
Phoenix, ArizonaAges 18 years+ - NCT04566380RecruitingPhase 2
Study for people already taking ONO-4538
This trial is for people who are already being treated with ONO-4538 (either alone or with other treatments) and can continue into an “extension/rollover” study. It checks how well ONO-4538 continues to work and is used safely over more time.
Kashiwa, ChibaAges 16 years+ - NCT06208410RecruitingPhase 1/Phase 2
JS105 plus other treatments for advanced solid tumors
This trial tests a new drug called JS105 combined with other anti-cancer therapies for people with certain advanced breast, ovarian, endometrial, or cervical cancers. It aims to find out if these combinations are safe and effective.
Zhengzhou, HenanAges 18–75 - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Phoenix, ArizonaAges 18 years+
Hear when a new Capecitabine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for capecitabine?
- Yes. Clin2 currently lists 288 recruiting capecitabine studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a capecitabine trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a capecitabine trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.